Intuitive Surgical (ISRG) presents a bullish thesis with a market capitalization of $122.3 billion, trailing P/E of 39.7, EPS of $8.70, and robust TTM revenue of $11.03 billion. Quarterly revenue growth of 18.5% and earnings growth of 26.5% underscore strong momentum in the robotic surgery space, supported by a profit margin of 28.4%. The forward P/E of 33.22 suggests reasonable valuation relative to growth prospects.
Key catalysts include continued adoption of the da Vinci Surgical System, expansion into new surgical procedures, and positive earnings momentum with analyst target price at $504.15. Recent quarterly results reflect sustained demand for minimally invasive robotic solutions, driving market share gains in healthcare.
Risks encompass regulatory hurdles for new device approvals, intense competition from emerging robotic platforms, and macroeconomic pressures like hospital capital spending constraints. Mitigations involve Intuitive's established regulatory expertise, strong IP portfolio, and diversified global revenue streams that buffer against regional economic volatility.
Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.
Get Deeper Analysis
Ask Theo anything about ISRG — earnings, valuation, technicals, or portfolio fit.
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Fundamental Snapshot
Revenue
11.0344B
EBITDA
4.1808B
Gross Profit
7.3576B
Operating Margin
33.6%
Profit Margin
28.4%
ROE
17.4%
Book Value
$49.31
Beta
1.46
52-Wk High
$603.88
52-Wk Low
$328.57
Avg Volume
3.4354M
PEG Ratio
1.735
Frequently Asked Questions
What is Intuitive Surgical's business model?
Intuitive Surgical develops, manufactures, and markets robotic surgical systems, primarily the da Vinci platform, generating revenue through system sales, recurring instrument and accessory sales, and service contracts. With TTM revenue of $11.03 billion and gross profit of $7.37 billion, the model emphasizes high-margin recurring revenue from procedures.
What are ISRG's main revenue sources?
Revenue primarily comes from da Vinci system placements, instruments and accessories used in procedures, and ongoing service/maintenance. TTM revenue reached $11.03 billion with 18.5% quarterly growth, reflecting strong procedure volume and system utilization across hospitals worldwide.
What competitive advantages does ISRG hold?
ISRG benefits from a dominant market position in robotic surgery, extensive clinical data, and a large installed base of da Vinci systems. Its 28.4% profit margin, 39.7 trailing P/E, and 90.4% institutional ownership highlight barriers to entry and technological leadership versus competitors.
What are the key risks for ISRG investors?
Key risks include regulatory approval delays, competition in robotics, and hospital budget constraints amid macro headwinds. With beta of 1.46 and no dividend (yield null), the stock shows volatility; mitigations stem from its $122.3B market cap scale and proven earnings growth of 26.5% YoY.
What is the growth outlook for ISRG?
Growth outlook remains positive with analyst target of $504.15, forward P/E of 33.22, and continued expansion in minimally invasive procedures. Quarterly EPS of $8.70 and revenue growth of 18.5% support long-term momentum, though investors should monitor earnings dates for updates.
